Sign In
Buy ABBV
$224.93
+7.86 (+3.62%)
At Close: Jun 04, 2026
– BLA based on data from the global Phase 1/2 CADENZA trial NORTH CHICAGO, Ill. , Sept. 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced submission of a new Biologics License Application
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
07:30pm, Monday, 29'th Sep 2025
Tokyo, Japan and Cambridge and London, UK, 30 September 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a second important R&D milestone unde
AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease
03:41pm, Monday, 29'th Sep 2025
ABBV files for FDA approval of tavapadon, a once-daily oral Parkinson's drug backed by late-stage TEMPO studies.
AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility
12:00pm, Monday, 29'th Sep 2025
New state-of-the-art active pharmaceutical ingredient (API) facility will manufacture immunology, oncology and neuroscience medicines Facility expected to be fully operational and serving patients by
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
10:01am, Monday, 29'th Sep 2025
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
AbbVie to launch ovarian cancer drug in UK at the same list price as US
09:11am, Monday, 29'th Sep 2025
AbbVie said on Monday it would launch its ovarian cancer drug Elahere in the U.K. at a list price equal to that in the U.S.
AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)
09:00am, Monday, 29'th Sep 2025
The list price will be consistent with the United States to reflect the value of the innovation AbbVie is committed to ensuring that developed nations fully recognize the value of our medicines in imp
5 Dividend Powerhouses to Buy and Never Sell
10:00am, Sunday, 28'th Sep 2025
Here's a statistic that should reshape how you think about investing: Companies that consistently raise dividends have crushed the S&P 500 by 2.5 percentage points annually since 1972. Not tech highfl
AbbVie For Healthy Dividend Growth
07:00am, Saturday, 27'th Sep 2025
AbbVie is rated a strong buy for its strong dividend growth, robust fundamentals, and proven track record as a Dividend King. ABBV offers a compelling mix of a 3% yield and nearly 7% annual historical
Many pharma companies already made U.S. investment promises, says Citi's Geoff Meacham
04:50pm, Friday, 26'th Sep 2025
CNBC's “Closing Bell Overtime” team discusses President Trump's plan to impose a 100% tariff on “all any branded or patented Pharmaceutical Product” entering the U.S. with Geoff Meacham of Cit
Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE?
12:46pm, Friday, 26'th Sep 2025
ABBV eyes a 2025 rebound as Skyrizi and Rinvoq drive growth beyond Humira, with oncology and neuroscience adding momentum.
AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease
08:45am, Friday, 26'th Sep 2025
Submission supported by data from the Phase 3 TEMPO program that demonstrated symptomatic improvement across the Parkinson's disease spectrum Positive results across all three Phase 3 TEMPO trials rei
AbbVie's Rinvoq Gains Early Traction in Giant Cell Arteritis Market, Expanding Options for Rheumatologists
11:53am, Thursday, 25'th Sep 2025
Spherix Global Insights finds majority of specialists expect Rinvoq's uptake to accelerate, with potential implications branching to the polymyalgia rheumatica landscape. Spherix Global Insights finds
3 Top Dividend Stocks to Buy and Hold Forever
05:00am, Thursday, 25'th Sep 2025
Dividends have quietly driven the bulk of stock market returns for over a century. While share prices grab headlines, reinvested dividends account for the majority of total returns in global equity ma
Allergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai
05:00am, Thursday, 25'th Sep 2025
New AA (Allergan Aesthetics) Signature™ multimodal treatment approach to be presented at AMWC Dubai following successful launch in 25 countries so far this year. Experts to explore the paradigm shif
